The invention provides columns (including pipette tip columns) and automated methods for the purification of nucleic acids including plasmids. Nucleic acids can be purified from unclarified, clarified or partially-clarified cell lysates that contain cell debris. The columns typically include a bed of medium positioned above a bottom frit and with an optional top frit. Plasmid preparation scales include miniprep, midiprep, maxiprep, megaprep and gigaprep.

Provided herein are, inter alia, biological manufacturing and downstream purification processes.

The present invention relates to an insulin precursor purifying method for improving the production yield of an insulin precursor by adjusting the pHs of a first buffer solution for equilibrating an ion exchange resin and a second buffer solution for eluting an insulin precursor bound to the ion exchange resins. The insulin precursor purifying method according to the present invention is a high-purity and high-yield insulin precursor purifying method for reinforcing by mean of suitable pH combination of buffer solutions, the binding force of an insulin precursor to ion exchange resins and enabling the insulin precursor to be effectively eluted thereafter, and is very useful in high-yield insulin production through enzymatic conversion after a purification process.

The present invention discloses a microencapsulation method for improving stability of anthocyanin, a product therefrom and use thereof. A preparation method of anthocyanin microcapsules includes: (1) taking sodium alginate as a wall material, adding sodium alginate and calcium carbonate into water, and swelling for 1-2 h to obtain a wall material gel system; (2) taking anthocyanin prepared by a special process as a core material, and fully and uniformly mixing the wall material gel system with an anthocyanin solution to obtain a water phase; (3) mixing Span80 and vegetable oil to obtain an oil phase, mixing the water phase with the oil phase, and magnetically stirring for emulsifying to obtain a W/O emulsion; and (4) adjusting the pH of the W/O emulsion to be acidic, mixing the W/O emulsion with a salt buffer solution, standing for 1-2 h, and then separating the oil phase and the water phase.

Methods, sorbent cartridges and cleaning devices are disclosed for refurbishing sorbent materials. In one implementation among multiple implementations, a medical fluid delivery method includes: providing a sorbent cartridge including H.sup.+ZP within a casing for a treatment; and after the treatment, refurbishing the H.sup.+ZP while maintained within the casing via (i) regenerating the non-disinfected H.sup.+ZP by flowing an acid solution through the casing, (ii) rinsing the regenerated H.sup.+ZP while maintained within the casing, (iii) disinfecting the regenerated and rinsed H.sup.+ZP by flowing a disinfecting agent through the casing, and (iv) rinsing the regenerated and disinfected H.sup.+ZP while maintained within the casing. Multiple batch sorbent refurbishing implementations are also disclosed.

A chromatographic method for separation of lipid-membrane-enclosed compound assemblages (LMCAs) from chromatin heteroaggregates including degraded remnants from LMCAs in a sample, contacting the sample with a chromatographic material with a surface having cationic metal affinity ligands said chromatographic material being charged with ferric iron, manganese, calcium, or magnesium ions, and being equilibrated with an equilibration buffer, applying a gradient of a first elution buffer comprising a non-metal-chelating salt, thereby eluting LMCAs.

A process for transglucosylation of steviol glycosides. A sweetener composition comprises at least 95% total glycosylated steviol glycosides.

The invention relates to a method for chromatographic separation, comprising at least one step of elution of species held on a stationary phase by means of an eluent, followed by a step of moving the eluent in contact with the stationary phase by means of a compressed gas. Preferably, the movement step takes place after a step of elution of the product(s) of interest and/or after a step of regeneration of the stationary phase.

The present invention relates to an apheresis device (1) for the extracorporeal removal of C-reactive protein from blood of a patient, wherein the apheresis device is connectable to the blood circulation of the patient. The blood is pumped via a part of the extracorporeal circulation system (2) of the apheresis device (1) according to the invention to a cell separator (7) for separation of the blood into blood plasma and cellular components. Via a first outlet of the cell separator (7), the separated blood plasma is directed by means of a plasma line (8A) to an apheresis column (4) for affinity chromatographic removal of C-reactive protein from the blood plasma. After removal of the C-reactive protein from the blood plasma of the patient, said now treated blood plasma is combined with the cellular components of the blood via a plasma line (8B). Furthermore, the apheresis device (1) according to the invention comprises a bypass line (12), which leads from the plasma line (8A) into the plasma line (8B) while bypassing the apheresis column (4). The apheresis device (1) according to the invention also comprises a regeneration line (14), which runs into the plasma line (8A) or directly into the apheresis column (4).

According to one embodiment, a method for removing antimicrobial material from a composition includes providing a container that contains a plurality of carbon elements such as granules, rocks and sheets. The carbon elements are submerged with a liquid and a composition that includes an antimicrobial material is deposited in the container. The carbon elements are configured to remove the antimicrobial material from the composition. The level of the liquid in the container is monitored and controlled to maintain a submerged condition of the carbon elements.